Prof. Dr Iris Löw-Friedrich Chief Medical Officer of UCB S.A., Chairperson of the Supervisory Board of Evotec SE

Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Since 15 June 2021 she has been serving as chairwoman of the Supervisory Board. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since March 2008, Prof. Dr Iris Löw-Friedrich is serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium).

From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen.

From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB.

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000.

She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985. Prof Dr Iris Löw-Friedrich is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

 

Latest update: June 2021

Roland Sackers Chief Financial Officer and Managing Director of QIAGEN N.V., Vice Chairman of the Supervisory Board of Evotec SE

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as board member of BIO Deutschland e.V. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

 

Latest update: June 2021

Dr Mario Polywka Consultant

Dr Mario Polywka (born in 1963, British citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Dr Polywka retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007.

In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2000 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994.

Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd. In September 2019, Dr Polywka was appointed Non-Executive Director at the UK biotech company Orbit Discovery, and has accepted a position as Senior Advisor with MCF Corporate Finance.

Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent.

 

Latest update: June 2021

Dr Elaine Sullivan CEO of Curadh Pharmaceuticals and Advisor to the Board of Directors of Carrick Therapeutics Ltd.

Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since April 2020, Dr Sullivan is CEO of Curadh Pharmaceuticals. From 2015 to 2019, Dr Sullivan was Chief Executive Officer of Carrick Therapeutics Ltd, a European oncology company, which she continues to support as Executive Entrepreneur and Advisor to the Board of Directors.

Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca. She has over 25 years of international experience working in the Pharmaceutical industry in the USA and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.

Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca‘s virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships.

Since July 2015, Dr Elaine Sullivan has been serving as Non-executive Director of the IP Group plc. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.

Dr Elaine Sullivan (the former CEO of Carrick Therapeutics Ltd) is independent. Evotec SE holds approximately 4.5% of the shares in Carrick Therapeutics Ltd., and it is not a significant partner of Carrick Therapeutics Ltd. at present.

Therefore, for two reasons there is no conflict of interest that could hinder the position of independence:

  1. Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Management Board of Evotec SE on its own responsibility pursuant to section 76 paragraph 1 of the German Stock Corporation Act (AktG). In particular, a member of the Supervisory Board has no influence on the voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. (e.g. on any formal approval).
  2. There is also no intersecting executive body position, nor are there any other significant connections to members of the company's Management Board through their involvement in other companies or organisations.

 

Latest update: June 2021

Kasim Kutay Chief Executive Officer at Novo Holdings A/S

Mr Kasim Kutay (born 1965, British citizen) was appointed Member of the Supervisory Board on 16 June 2020. His current term will expire at the end of the Annual General Meeting charged with approving the actions of the members of the Supervisory Board in the 2023 fiscal year.

Since September 2016, Mr Kutay is the Chief Executive Officer of Novo Holdings A/S. From 2009 until 2016, Mr. Kutay served as Managing Director, Co-Head of Europe and member of the Global Management Committee at Moelis & Co. Prior to that, Mr. Kutay spent 18 years with Morgan Stanley in various international senior management positions, including as Chairman of the European Healthcare Group. In these positions, Mr. Kutay has worked with healthcare companies on an international basis, including companies based in Europe, the USA, Japan and India, among others. Mr. Kutay’s other board positions include member of the Supervisory Boards of Novo Nordisk A/S and Novozymes A/S.

He received his degree Master of Science from the London School of Economics. Mr. Kasim Kutay is considered an independent member of the Supervisory Board despite his position as Chief Executive Officer of Novo Holdings A/S. Novo Holding A/S holds just over 10 % of the voting shares in Evotec SE and is therefore not a controlling shareholder.

A control leading to the independence of the shareholder (and thus also of Mr. Kutay) would be given if a control agreement with the shareholder existed, the shareholder had an absolute majority of the voting rights or at least a sustainable majority at the Annual General Meeting. A share of just over 10 % of the voting rights does not constitute a sustainable majority in favour of Novo Holdings A/S and therefore does not constitute a conflict of interest, especially as the number of valid votes cast at previous general meetings regularly amounted to well over 40 % of the share capital.

 

Latest update: June 2021

Dr Constanze Ulmer-Eilfort Partner of the law firm Baker McKenzie, Member of the Global Executive Committee

Dr Ulmer-Eilfort has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. She advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions. As a member of the Global Executive Committee of Baker McKenzie, Dr Ulmer-Eilfort chairs the Global Financial Committee and oversees the budgeting process and budget controls worldwide.

In addition, she is leading the reform of governance at Baker McKenzie, a multi-year project which includes the introduction of a new supervisory board that aims to support the engagement of partners, build trust and make management more accountable. Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions (e.g. as Chair of the Financial Committee) as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is chairwoman of the advisory committee of S4DX GmbH. Otherwise she is not a member of any statutory supervisory boards or similar domestic or foreign supervisory boards of commercial entities in accordance with Sec. 125 para. 1 sentence 5 AktG and recommendation C.14 of the German Corporate Governance Code as amended on 16 December 2019.

 

Latest update: June 2021

CVs of all Supervisory Board members of Evotec SE

TOP